Literature DB >> 18223326

HSD3B1 as a novel trophoblast-associated marker that assists in the differential diagnosis of trophoblastic tumors and tumorlike lesions.

Tsui-Lien Mao1, Robert J Kurman, Yung-Ming Jeng, Wilber Huang, Ie-Ming Shih.   

Abstract

Trophoblastic tumors and tumorlike lesions can be confused with a variety of nontrophoblastic tumors; therefore, a trophoblast-associated marker that is expressed in all types of trophoblastic lesions is useful in differential diagnosis. In this report, we assessed the potential of hydroxyl-delta-5-steroid dehydrogenase (HSD3B1), an enzyme that catalyzes the oxidative conversion of delta-5-3 beta-hydroxy steroids to the delta-4-3-keto configuration and that is involved in steroid hormone synthesis, as a diagnostic trophoblastic marker. First, the gene expression profile of HSD3B1 was analyzed in silica using serial analysis of gene expression in the database deposited in the public domain and found that HSD3B1 was not expressed in 159 libraries of breast, lung, colorectal, pancreatic, ovarian carcinomas, and a wide variety of normal adult and fetal tissues. Second, an immunohistochemical analysis was performed using a commercially available anti-HSD3B1 monoclonal antibody on paraffin sections. HSD3B1 immunoreactivity was detected in intermediate trophoblast and syncytiotrophoblast in 21 early placentas, 18 complete hydatidiform moles, 67 trophoblastic tumors, including placental site trophoblastic tumors, epithelioid trophoblastic tumors, and choriocarcinomas, and 28 tumorlike lesions including placental site nodules and exaggerated placental site. HSD3B1 immunoreactivity was diffuse and intense in the majority of trophoblastic lesions with the exception of a few choriocarcinomas. In contrast, only 3 (<1%) of 319 nontrophoblastic carcinomas from the uterus, lung, and breast reacted with the HSD3B1 antibody. Moreover, the immunoreactivity in these lesions was focal and weak. In conclusion, as compared with other trophoblastic markers, HSD3B1 is highly specific and sensitive, being expressed in all types of trophoblastic lesions but not in a variety of nontrophoblastic tumors of the uterus, lung, and breast.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18223326     DOI: 10.1097/PAS.0b013e31812e0046

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  5 in total

1.  GATA-3 expression in trophoblastic tissues: an immunohistochemical study of 445 cases, including diagnostic utility.

Authors:  Natalie Banet; Allen M Gown; Ie-Ming Shih; Qing Kay Li; Richard B S Roden; Marisa R Nucci; Liang Cheng; Christopher G Przybycin; Niloofar Nasseri-Nik; Lee-Shu-Fune Wu; George J Netto; Brigitte M Ronnett; Russell Vang
Journal:  Am J Surg Pathol       Date:  2015-01       Impact factor: 6.394

2.  Trophoblast deportation to the lungs of cotton rats (Sigmodon hispidus).

Authors:  Krista M D La Perle; M Gia Green; Stefan Niewiesk
Journal:  Comp Med       Date:  2014-12       Impact factor: 0.982

3.  [Histopathology of gestational trophoblastic disease. An update].

Authors:  L-C Horn; J Einenkel; M Vogel
Journal:  Pathologe       Date:  2009-07       Impact factor: 1.011

4.  Evidence for Placental HPV Infection in Both HIV Positive and Negative Women.

Authors:  Chrispin Chisanga; Dawn Eggert; Charles D Mitchell; Charles Wood; Peter C Angeletti
Journal:  J Cancer Ther       Date:  2015-12-25

Review 5.  Unusual Faces of Bladder Cancer.

Authors:  Claudia Manini; José I López
Journal:  Cancers (Basel)       Date:  2020-12-10       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.